<DOC>
	<DOCNO>NCT00791765</DOCNO>
	<brief_summary>The purpose study determine etanercept effective treatment scalp involvement moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Moderate Severe Plaque Psoriasis With Scalp Involvement</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Must provide write informed consent studyspecific procedure Be male female great equal 18 year age time screening Has stable moderate severe plaque psoriasis least 6 month Affected body surface area ( BSA ) great equal 10 % Psoriasis Area Severity Index ( PASI ) score great equal 10 At least 30 percent affect scalp surface area Psoriasis Scalp Severity Index ( PSSI ) score great equal 15 Candidate systemic therapy phototherapy opinion investigator Negative test hepatitis B surface antigen , hepatitis C antibody , Human Immunodeficiency Virus ( HIV ) Negative serum pregnancy test female subject ( unless 3 year post menopausal surgically sterile ) Willing use medically acceptable form birth control duration study Negative Purified Protein Derivative ( PPD ) within 30 day prior first dose study drug Any active infection Significant concurrent medical condition , include : Insulin dependent diabetes mellitus ; Congestive heart failure ; Myocardial infarction within last year ; Unstable angina pectoris ; Uncontrolled hypertension ; Severe pulmonary disease [ require oxygen therapy hospitalization ] ; Systemic lupus erythematosus ; Multiple sclerosis demyelinate disease ; Active malignancy Any condition , opinion study doctor , might cause study detrimental subject History cancer within 5 year first dose study drug Skin condition psoriasis would interfere evaluation effect study medication psoriasis Presence guttate , erythrodermic pustular psoriasis Use topical cyclosporine calcineurin inhibitor within 14 day first dose study drug Use tar shampoo within 14 day first dose study drug Use follow therapy within 28 day first dose study drug : IV oral cyclosporine calcineurin inhibitor , Ultraviolet Light A therapy , Psoralen plus ultraviolet A radiation , Oral retinoids , Ultraviolet Light B therapy , Topical steroid steroid shampoo , Topical vitamin A D analog preparation , Anthralin , systemic psoriasis therapy , cyclophosphamide , sulfasalazine , anakinra Use Alefacept ( Amevive ) , Efalizumab ( Raptiva ) , Antitumor necrosis factor ( TNF ) biologic therapy within 3 month first dose study drug . Prior antiTNF use permit discontinue due lack efficacy , adverse event , noncompliance . Use interleukin ( IL ) 12/IL23 within 6 month first dose study drug Participation another clinical trial within 90 day 5 halflives ( whichever longer ) randomization Laboratory abnormality screen : hemoglobin le 11 g/dL , platelet count less 125,000/mm^3 , white blood cell count le 3,500 cells/mm^3 , aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) great equal 1.5 x upper limit normal , laboratory abnormality prevent patient complete study interfere interpretation study result Patient pregnant breast feed Presence condition could compromise patient 's ability participate study , history substance abuse psychiatric condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Scalp</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Skin Diseases</keyword>
	<keyword>Moderate severe plaque psoriasis</keyword>
	<keyword>etanercept</keyword>
</DOC>